Alzheimer's disease drug development pipeline: 2017

There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies.

• Publication year

  2017

• Venue

  Alzheimer's & Dementia

• Publication date

  2017-05-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.trci.2017.05.002PMID 29067343PMCID 5651419
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• alzheimer's disease

  disease

  A progressive neurodegenerative disease that is the therapeutic target discussed in the pipeline review.

  Aliases: AD

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewAnonymous (12632b8b5f) reviewmexicorea (qjvnbu8xg3) review
• drug development pipeline

  process

  The staged process used to discover, test, and advance candidate therapies toward approval for Alzheimer's disease.

  Aliases: development pipeline, pipeline

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewAnonymous (12632b8b5f) reviewmexicorea (qjvnbu8xg3) review
• drug development process

  process

  The sequence of research, testing, and evaluation steps involved in bringing Alzheimer's therapies forward.

  Aliases: development process

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewAnonymous (12632b8b5f) reviewmexicorea (qjvnbu8xg3) review
• new treatments

  therapeutic candidate

  Novel therapeutic options being sought for Alzheimer's disease.

  Aliases: therapies, new therapies

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewAnonymous (12632b8b5f) reviewmexicorea (qjvnbu8xg3) review

• The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

  2017cited by this paper
• Merck ends trial of potential Alzheimer’s drug verubecestat

  2017cited by this paper
• Titration dosing of aducanumab: Results of a 12-month interim analysis from a randomized, double-blind, placebo-controlled Phase 1b study (PRIME) in patients with prodromal or mild Alzheimer’s Disease (S7.003)

  2017cited by this paper
• Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors

  2016cited by this paper
• Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.

  2016cited by this paper
• Toward a New Era of Trust and Transparency in Clinical Trials.

  2016cited by this paper
• Alzheimer's drug-development pipeline: 2016

  2016cited by this paper
• Symptomatic Cognitive Enhancing Agents

  2016cited by this paper
• Solanezumab and the amyloid hypothesis for Alzheimer’s disease

  2016cited by this paper
• Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

  2016cited by this paper
• New directions for protease inhibitors directed drug discovery

  2016cited by this paper
• The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

  2016cited by this paper
• Drug development in Alzheimer’s disease: the path to 2025

  2016cited by this paper
• Trial Reporting in ClinicalTrials.gov - The Final Rule.

  2016cited by this paper
• Alzheimer's disease research in the context of the national plan to address Alzheimer's disease.

  2015cited by this paper
• Revolutionizing Alzheimer's disease and clinical trials through biomarkers

  2015cited by this paper
• DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study

  2015cited by this paper
• 2015 Alzheimer's disease facts and figures

  2015cited by this paper
• The need for thorough phase II studies in medicines development for Alzheimer’s disease

  2015cited by this paper
• Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

  2014cited by this paper
• β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease

  2014cited by this paper
• Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

  2014cited by this paper
• Economic analysis of opportunities to accelerate Alzheimer’s disease research and development

  2014cited by this paper
• Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets

  2014cited by this paper
• Parallel Discovery of Alzheimer’s Therapeutics

  2014cited by this paper
• Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects

  2014cited by this paper
• Repackaging FDA-approved drugs for degenerative diseases: promises and challenges

  2014cited by this paper
• Discovering new treatments for Alzheimer's disease by repurposing approved medications.

  2013cited by this paper
• A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents

  2013cited by this paper
• 2013 Alzheimer's disease facts and figures

  2013cited by this paper
• Commercializing biomedical research through securitization techniques

  2012cited by this paper
• Globalization of Alzheimer's disease clinical trials

  2011cited by this paper
• Amyloid‐related imaging abnormalities in amyloid‐modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup

  2011cited by this paper
• Biomarkers in Alzheimer's disease drug development

  2011cited by this paper
• Adaptive design clinical trials and trial logistics models in CNS drug development.

  2011cited by this paper
• Biomarkers in Alzheimer's disease drug development

  2010cited by this paper
• Principles of CNS drug development : from test tube to patient

  2009cited by this paper
• Issues in the registration of clinical trials.

  2007cited by this paper
• Partnerships between philanthropy, government and industry are needed to advance drug discovery for neurodegenerative diseases.

  2006cited by this paper
• Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

  2005cited by this paper
• Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

  2004cited by this paper
• Phase I: The First Opportunity for Extrapolation from Animal Data to Human Exposure

  2002cited by this paper
• Phase I clinical trials.

  1977cited by this paper
• Phase II clinical trials.

  1977cited by this paper

• Beyond the streetlight: a TREAT‐AD perspective on where to find new Alzheimer's targets

  2026cites this paper
• Baicalein's neuroprotective effects in a lansoprazole-induced Alzheimer's model in Wistar rats

  2025cites this paper
• Procognitive Potential of Neuroprotective Triazine 5-HT6 Receptor Antagonists Tested on Chronic Activity In Vivo in Rats: Computer-Aided Insight into the Role of Chalcogen-Differences on the Pharmacological Profile

  2025cites this paper
• The "five-star matrix" for patient-centric drug discovery and development in neuroscience.

  2025cites this paper
• Modified bentonite @ microwave for Mn(VII) removal with a simulation study

  2025cites this paper
• The evolving landscape of Alzheimer's disease therapy: From Aβ to tau.

  2025cites this paper
• Inter-network functional connectivity increases by beta-amyloid and may facilitate the early stage of tau accumulation.

  2025cites this paper
• Comprehensive Evaluation of Pre-trained Neural Networks for Alzheimer’s Disease Classification Using Transfer Learning

  2025cites this paper
• Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024

  2025cites this paper
• Isobavachalcone ameliorates Alzheimer disease pathology by autophagy-mediated clearance of amyloid beta and inhibition of NLRP3 inflammasome in primary astrocytes and 5x-FAD mice

  2025cites this paper
• State-of-the-art surfactant-based coatings for biomaterials: Innovations, applications, and future prospects in biomedical engineering.

  2025cites this paper
• Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer’s Disease

  2024cites this paper
• Recent Progress in Alzheimer’s Disease: Pathophysiology, Newer Natural & Synthetic Inhibitors, and Therapeutic Targets

  2024cites this paper
• Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7.

  2024cites this paper
• Comparison between dynamic versus static models and real-time monitoring of neuronal dysfunction in an amyloid-β induced neuronal toxic model on a chip platform.

  2024cites this paper
• A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD).

  2024cites this paper
• Senescence-Associated Microvascular Endothelial Dysfunction: A Focus on the Blood-Brain and Blood-Retinal Barriers.

  2024cites this paper
• From Alzheimer’s Disease to Anxiety, Epilepsy to Schizophrenia: A Comprehensive Dive Into Neuro-Psychiatric Disorders

  2024cites this paper
• Present and future use of exosomes containing proteins and RNAs in neurodegenerative diseases for synaptic function regulation: A comprehensive review.

  2024cites this paper
• Unveiling the potential of novel indol-3-yl-phenyl allylidene hydrazine carboximidamide derivatives as AChE/BACE 1 dual inhibitors: a combined in silico, synthesis and in vitro study

  2024cites this paper
• Dysregulated AEBP1 and COLEC12 Genes in Late-Onset Alzheimer’s Disease: Insights from Brain Cortex and Peripheral Blood Analysis

  2024cites this paper
• People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare

  2023cites this paper
• Efficacy of acupuncture in patients with mild Alzheimer’s disease and its impact on gut microbiota: Study protocol for a randomized sham-controlled trial

  2023cites this paper
• Exploring the potential of targeting insulin-like growth factor-1 through network pharmacology, molecular docking, molecular dynamics, and experimental validation of antioxidant and anti-inflammatory activities

  2023cites this paper
• Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.

  2023cites this paper
• Nanotechnology-empowered therapeutics targeting neurodegenerative diseases.

  2023cites this paper
• Failure, Success, and Future Direction of Alzheimer Drugs Targeting Amyloid‐β Cascade: Pros and Cons of Chemical and Biological Modalities

  2023cites this paper
• Synthesis of Beta-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitors BI 1147560 and BI 1181181 Labeled with Carbon-14 and Deuterium.

  2023cites this paper
• Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

  2023cites this paper
• Gamma connectivity predicts response to intermittent theta burst stimulation in Alzheimer's disease: a randomized controlled trial.

  2023cites this paper
• Ability and Willingness to Participate in Dementia Clinical Research: A Qualitative Study

  2023cites this paper
• Resting-state electroencephalographic characteristics related to mild cognitive impairments

  2023cites this paper
• Progressive Motor and Non-Motor Symptoms in Park7 Knockout Zebrafish

  2023cites this paper
• The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer’s Disease

  2023cites this paper
• Therapeutic effects of crude extracts of Bacopa floribunda on beta-amyloid 1-42-induced Alzheimer’s disease via suppression of dyslipidemia, systemic inflammation and oxidative stress in male Wistar Rats

  2022cites this paper
• Experimental modelling of Alzheimer’s disease for therapeutic screening

  2022cites this paper
• Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults

  2022cites this paper
• Advances in the development of new biomarkers for Alzheimer’s disease

  2022cites this paper
• Network-based stage-specific drug repurposing for Alzheimer’s disease

  2022cites this paper
• Design, synthesis and evaluation of novel scutellarin and scutellarein-N,N-bis-substituted carbamate-l-amino acid derivatives as potential multifunctional therapeutics for Alzheimer's disease.

  2022cites this paper
• The road to precision medicine: Eliminating the "One Size Fits All" approach in Alzheimer's disease.

  2022cites this paper
• Integrated analyses of brain and platelet omics reveal their common altered and driven molecules in Alzheimer's disease

  2022cites this paper
• Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges

  2022cites this paper
• Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors

  2022cites this paper
• Anti-fibrillization effects of sulfonamide derivatives on α-synuclein and hyperphosphorylated tau isoform 1N4R.

  2022cites this paper
• Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials

  2022cites this paper
• In Silico Screening of Natural Compounds for Candidates 5HT6 Receptor Antagonists against Alzheimer’s Disease

  2022cites this paper
• Regenerative medicine improve neurodegenerative diseases

  2022cites this paper
• Genetic and multi‐omic risk assessment of Alzheimer's disease implicates core associated biological domains

  2022cites this paper
• A Review of the Recent Advances in Alzheimer’s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics

  2022cites this paper
• Saponins and flavonoids from Bacopa floribunda plant extract exhibit antioxidant and anti-inflammatory effects on amyloid beta 1-42-induced Alzheimer's disease in BALB/c mice.

  2022cites this paper
• Evaluation of neuroprotective effects of Canna indica L against aluminium chloride induced memory impairment in rats

  2022cites this paper
• Photobiomodulation for Hypertension and Alzheimer’s Disease

  2022cites this paper
• Monitoring HDAC4 Expression in Alzheimer’s Disease Using [18F]TFAHA-PET

  2022cites this paper
• Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review.

  2022cites this paper
• Aniba canelilla (Kunth) Mez essential oil and its primary constituent, 1-nitro-2-phenylethane, inhibits acetylcholinesterase and reverse memory impairment in rodents.

  2022cites this paper
• Alzheimer’s Disease: An Update and Insights Into Pathophysiology

  2022cites this paper
• Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease

  2022cites this paper
• Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology

  2022cites this paper
• AAV-mediated neuronal expression of a scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models

  2022cites this paper
• Exercise engagement drives changes in cognition and cardiorespiratory fitness after 8 weeks of aerobic training in sedentary aging adults at risk of cognitive decline

  2022cites this paper
• Exploring the zinc-related transcriptional landscape in Alzheimer’s disease

  2022cites this paper
• A Real-Time Sensing System for Monitoring Neural Network Degeneration in an Alzheimer’s Disease-on-a-Chip Model

  2022cites this paper
• Far infrared light irradiation enhances Aβ clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer’s disease-like mice

  2022cites this paper
• Residents’ satisfaction with sustainable tourism: the moderating role of environmental awareness

  2022cites this paper
• Alzheimer's disease drug development pipeline: 2022

  2022cites this paper
• AdipoRon induces AMPK activation and ameliorates Alzheimer's like pathologies and associated cognitive impairment in APP/PS1 mice.

  2022cites this paper
• A Machine Learning-Based Holistic Approach to Predict the Clinical Course of Patients within the Alzheimer’s Disease Spectrum

  2021cites this paper
• Dynamic 3D On-Chip BBB Model Design, Development, and Applications in Neurological Diseases

  2021cites this paper
• Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice

  2021cites this paper
• Early detection of Alzheimer’s disease using neuropsychological tests: a predict–diagnose approach using neural networks

  2021cites this paper
• Current druggable targets for therapeutic control of Alzheimer's disease.

  2021cites this paper
• Targeting both BDNF/TrkB pathway and delta-secretase for treating Alzheimer's disease.

  2021cites this paper
• The outcomes of small-molecule kinase inhibitors and the role of ROCK2 as a molecular target for the treatment of Alzheimer's disease.

  2021cites this paper
• Intranasal route: The green corridor for Alzheimer's disease therapeutics

  2021cites this paper
• Dementia Rehabilitation: The Challenges

  2021cites this paper
• Unraveling the Neuroprotective Effect of Tinospora cordifolia in a Parkinsonian Mouse Model through the Proteomics Approach.

  2021cites this paper
• Who funds Alzheimer's disease drug development?

  2021cites this paper
• Alzheimer's disease drug development pipeline: 2021

  2021cites this paper
• An Overview of β-Amyloid Cleaving Enzyme 1 (Bace1) in Alzheimer's Disease Therapy Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor.

  2021cites this paper
• Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy

  2021cites this paper
• Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals

  2021cites this paper
• A method for diagnosis support of mild cognitive impairment through EEG rhythms source location during working memory tasks

  2021cites this paper
• Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease

  2021cites this paper
• The Function of Selenium in Central Nervous System: Lessons from MsrB1 Knockout Mouse Models

  2021cites this paper
• Single molecule imaging of protein aggregation in Dementia: Methods, insights and prospects

  2021cites this paper
• QbD-Steered Development of Mixed Nanomicelles of Galantamine: Demonstration of Enhanced Brain Uptake, Prolonged Systemic retention and Improved Biopharmaceutical Attributes.

  2021cites this paper
• DJ-1 affects oxidative stress and pyroptosis in hippocampal neurons of Alzheimer's disease mouse model by regulating the Nrf2 pathway

  2021cites this paper
• Design, synthesis and evaluation of cinnamic acid hybrids as multi-target-directed agents for the treatment of Alzheimer's disease.

  2021cites this paper
• Unraveling the neuroprotective effect of Tinospora cordifolia in Parkinsonian mouse model through proteomics Approach.

  2021cites this paper
• “Ready for What?”: Timing and Speculation in Alzheimer’s Disease Drug Development

  2021cites this paper
• Efficacy of preclinical pharmacological interventions against alterations of neuronal network oscillations in Alzheimer's disease: A systematic review.

  2021cites this paper
• Mesenchymal Stem Cell-Derived Exosomes Ameliorate Alzheimer’s Disease Pathology and Improve Cognitive Deficits

  2021cites this paper
• The relationship of semantic intrusions to different etiological subtypes of MCI and cognitively healthy older adults

  2021influential citation
• The application of multifunctional nanomaterials in Alzheimer's disease: A potential theranostics strategy.

  2021cites this paper
• A Signature of Five Long Non-Coding RNAs for Predicting the Prognosis of Alzheimer's Disease Based on Competing Endogenous RNA Networks

  2021cites this paper
• SANE: A sequence combined attentive network embedding model for COVID-19 drug repositioning

  2021cites this paper
• Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer’s Disease

  2021cites this paper
• Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.

  2021cites this paper
• Bilingualism: Pathway to Cognitive Reserve.

  2021cites this paper